In the BioHarmony Drug Report Database

"Preview" Icon

Caplacizumab-yhdp

Cablivi (caplacizumab) is an antibody pharmaceutical. Caplacizumab was first approved as Cablivi on 2018-08-30. It has been approved in Europe to treat thrombotic thrombocytopenic purpura. The pharmaceutical is active against von Willebrand factor.

 

Trade Name

 

Cablivi
 

Common Name

 

caplacizumab
 

ChEMBL ID

 

CHEMBL2109624
 

Indication

 

thrombotic thrombocytopenic purpura
 

Drug Class

 

Monoclonal antibodies: humanized, cardiovascular indications

Image (chem structure or protein)

Caplacizumab-yhdp structure rendering